Listen to our expert faculty discuss multidisciplinary treatment decisions for amyloid light-chain amyloidosis (AL), including cardiac and renal care, treatment tolerability and frailty. They also explore emerging fibril-directed therapies and their potential role alongside plasma-cell–directed treatment, informed by clinical evidence and local approval.
The multidisciplinary team:
Hematologist – Dr. Yawara Kawano, Kumamoto University Hospital, Kumamoto City, Japan
Cardiologist – Dr. Christian Nitsche, Medical University of Vienna, Vienna, Austria
Amyloidosis specialist with a renal focus – Dr. Paolo Milani, University of Pavia, Pavia, Italy
Amyloidosis MDT nurse/coordinator – Ms. Christine Chiti, Royal Free London NHS Foundation Trust, London, UK
This touchPODCAST is for healthcare professionals outside of the UK.
This activity is supported by an independent medical education grant from Alexion Pharma GmbH.
Jointly provided by Partners for Advancing Clinical Education and touchIME.
touchIME is an EBAC® accredited provider.
Podden och tillhörande omslagsbild på den här sidan tillhör
touchpodcast. Innehållet i podden är skapat av touchpodcast och inte av,
eller tillsammans med, Poddtoppen.
